Nanoparticles with Chiral Ligands

  • ChemPubSoc Europe Logo
  • Author: ChemNanoMat
  • Published Date: 19 October 2016
  • Source / Publisher: ChemNanoMat/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
thumbnail image: Nanoparticles with Chiral Ligands

Drug resistance and damage to healthy cells are both serious problems in cancer treatment. Many efforts have centered on using enzyme inhibition to induce cancer cell death, but challenges still remain.


Bing Xu and colleagues, Brandeis University, Waltham, MA, USA, have used chirality to control the reaction-diffusion (RD) of nanoparticles (NPs) for selectively inhibiting cancer cells. They used phosphorylated amino acids, either L-phosphotyrosine (L-pTyr) or D-phosphotyrosine (D-pTyr), to decorate commercially available nanoparticles.


Alkaline phosphatases (ALP), which are enzymes that are present in the cell culture, dephosphorylated the D-pTyr-decorated NPs much more slowly than the L-pTyr-decorated NPs. This rate difference causes the D-pTyr-decorated NPs to be mainly dephosphorylated on the cancer cells, while L-pTyr-decorated NPs were mainly dephosphorylated in the culture media. Without phosphate groups, the NPs are innocuous to cells.


The D-pTyr-decorated NPs adhered selectively to the cancer cells, resulting in poly(ADP-ribose)polymerase (PARP)-hyperactivation-mediated cell death. These results are the first example of chirality controlling RD process of NPs for inhibiting cancer cells. They illustrate a new route to develop anticancer nanomedicine.


 

Article Views: 1181

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH